Sinusoidal obstruction syndrome/veno-occlusive disease complication in lymphoma patients treated with oxaliplatin-based regimen: A case series report

Bernichon, Emilie; Daguenet, Élisabeth; Molla, Carlos Francisco de; Cornillon, Jérôme; Lejeune, Caroline; Casteillo, François; Guyotat, Denis; Tavernier, Emmanuelle

doi:10.1016/j.retram.2018.01.004

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to patient/hepatic-related risk factors, univariate analysis found that the aspartate aminotransferase:platelet ratio index and splenomegaly were associated with severe lesions of VOD/SOS. A potential association of oxaliplatin-based treatment and occurrence of VOD/SOS also was reported in 4 patients with lymphoma who underwent HSCT and had no other patient-related VOD/SOS risk factors [49].…”

Section: Vod/sos Risk Factors Associated With Nontransplantation-relamentioning

confidence: 81%

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Corbacioglu

Jabbour

Mohty

2019

Biology of Blood and Marrow Transplantation

129

View full text Add to dashboard Cite

A B S T R A C T Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) most commonly associated with high-intensity chemotherapies. The development of VOD/SOS may be rapid and unpredictable, and the importance of identifying risk factors to facilitate prompt diagnosis and timely treatment has become increasingly recognized. The reporting of new retrospective study data for adults and children and the emergence of novel anticancer therapies that may increase the risk of VOD/SOD also necessitate updates on risk factors, as provided in this review. The latest studies reporting VOD/SOS risk factors support previously published data, although the importance of patient-related factors, such as acute kidney injury, increased international normalized ratio, female sex (in children), and platelet refractoriness, is given greater emphasis in the recent data. Nontransplantation-related chemotherapies associated with increased risk for VOD/SOS include oxaliplatin and 5-fluorouracil chemotherapies. The novel antibody drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin are now reported in product labeling to pose risks for VOD/SOS based on clinical trial data; an expert consensus panel has issued recommendations for risk reduction measures with inotuzumab ozogamicin treatment, including VOD/SOS prophylaxis and limitation to 2 inotuzumab ozogamicin treatment cycles. A wide range of biomarkers, including genetic, hematologic, hepatic, and inflammatory factors, as well as novel diagnostic techniques such as thromboelastography and measures of liver stiffness, may further enhance future risk calculation for VOD/SOS, although none has been widely adopted. Continual monitoring for and recognition of VOD/SOS risk factors are essential for optimal management of this complication.

show abstract

Section: Vod/sos Risk Factors Associated With Nontransplantation-relamentioning

confidence: 81%

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Corbacioglu

Jabbour

Mohty

2019

Biology of Blood and Marrow Transplantation

129

View full text Add to dashboard Cite

show abstract

“…5 -7 Drug-induced SOS is also described in cancer patients in nontransplant settings following the use of chemotherapeutic agents, such as oxaliplatin or calicheamicin-based antibody-drug conjugates (ADCs). 8 -10…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7] Drug-induced SOS is also described in cancer patients in nontransplant settings following the use of chemotherapeutic agents, such as oxaliplatin or calicheamicin-based antibody-drug conjugates (ADCs). [8][9][10] Gemtuzumab ozogamicin (GO, Mylotarg) and Inotuzumab ozogamicin (InO, Besponsa) are ADCs comprised of anti-CD33 and anti-CD22 antibody, respectively, conjugated to a calicheamicin derivative. Both GO and InO have a black box warning for hepatotoxicity/SOS [10][11][12] with an overall estimated incidence of SOS in 9% of people following GO treatment 13 and in 1.5% of people following InO treatment.…”

Section: Introductionmentioning

confidence: 99%

Anatomic and Clinical Pathology Characterization of Drug-Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in Cynomolgus Macaques

et al. 2021

View full text Add to dashboard Cite

Sinusoidal obstruction syndrome (SOS) is a unique form of liver injury that occurs after exposure to chemotherapeutic drugs and toxins. The diagnosis of SOS in humans remains a challenge as the clinical criteria have low specificity and there are no reliable noninvasive biomarkers. The mechanism of injury is believed to be damage to liver endothelial cells, primarily sinusoidal endothelial cells (SECs), which leads to sinusoidal dilation, central venous fibrosis, and/or nodular regeneration. Nonclinical data suggest that this uncommon liver toxicity can be recapitulated in cynomolgus monkeys, and it is critical that pathologists are familiar with its characteristic clinicopathologic features. Elevations in liver enzymes, in particular aspartate aminotransferase, associated with isolated thrombocytopenia, should raise the suspicion of SEC injury for specific drug classes. Characterization of liver microscopic findings in monkeys benefits from the use of appropriate stains, such as reticulin stain, and VEGFR2 and CD34 immunohistochemical (IHC) stains. CD41 IHC demonstrates platelet accumulation in injured sinusoids, the likely cause of thrombocytopenia commonly reported in SOS. In conclusion, this report provides a comprehensive characterization of the pathology findings of drug-induced SOS in monkeys with the objectives of ensuring appropriate nonclinical recognition of the liability and informing clinical development strategy and monitoring.

show abstract

Antineoplastics

2018

Reactions Weekly

View full text Add to dashboard Cite

Sinusoidal obstruction syndrome/veno-occlusive disease complication in lymphoma patients treated with oxaliplatin-based regimen: A case series report

Cited by 6 publications

References 17 publications

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Anatomic and Clinical Pathology Characterization of Drug-Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in Cynomolgus Macaques

Antineoplastics

Contact Info

Product

Resources

About